Pipeline

  • KD-001; Ischemic heart Disease
    - Myocardial Ca²⁺ overload induced by ischemia/reperfusion (I/R) is a major element of myocardial dysfunction in heart failure.
    - CT-1106 plays important roles in the regulation of the phosphoinositol pathway and Ca²⁺ homeostasis in various types of cells.
  • KD-002; Rheumatoid Arthirits
    - The conjugate of Cell Penetrating Peptide (CPP) and Disease-modifying antirheumatic drug (DMARD)
    - To enhance transdermal delivery of DMARD, particularly strong effect for Minimize the toxicity of DMARD & lower dose and improve the usage
  • KD-002-M; SARS-COV2
    - Drug Repositioning Approach
    - 26 AA. peptide generated by Botox E
    - Confirmed inhibition of SARS-COV2 virus replication “In-Vitro”
  • KD-003-HR; Hyperhidrosis
    - Transdermal cosmetics for anti-sweating effect and its toxicity is much lower than that of Botox
    - 26 AA. peptide generated by Botox E
    - Inhibition of Neurotransmitter release by disrupting the vesicle fusion complex
  • KD-003-AW; Anti-Wrinkle
    - Transdermal cosmetics for anti-wrinkle effect and its toxicity is much lower than that of Botox
    - 26 AA. peptide generated by Botox E
    - Inhibition of Neurotransmitter release by disrupting the vesicle fusion complex
  • Immunosuppressant Drugs; Autoimmune Disease, Cytokine release syndrome
    - Recombinant protein of immune response regulators conjugated with CPP
    - To down-regulate overly activated immune system
pipeline_mobile3.png
KD-001; Ischemic heart Disease
- Myocardial Ca²⁺ overload induced by ischemia/reperfusion (I/R) is a major element myocardial dysfunction in heart failure.
- CT-1106 plays important roles in the regulation of the phosphoinositol pathway and Ca²⁺ homeostasis in various types of cells.
KD-002; Rheumatoid Arthirits
- The conjugate of Cell Penetrating Peptide (CPP) and Disease-modifying antirheumatic drug (DMARD)
- To enhance transdermal delivery of DMARD, particularly strong effect for Minimize the toxicity of DMARD & lower dose and improve the usage
KD-002-M; SARS-COV2
- Drug Repositioning Approach
- 26 AA. peptide generated by Botox E
- Confirmed inhibition of SARS-COV2 virus replication “In-Vitro”
KD-003-HR; Hyperhidrosis
- Transdermal cosmetics for anti-sweating effect and its toxicity is much lower than that of Botox
- 26 AA. peptide generated by Botox E
- Inhibition of Neurotransmitter release by disrupting the vesicle fusion complex
KD-003-AW; Anti-Wrinkle
- Transdermal cosmetics for anti-wrinkle effect and its toxicity is much lower than that of Botox
- 26 AA. peptide generated by Botox E
- Inhibition of Neurotransmitter release by disrupting the vesicle fusion complex
Immunosuppressant Drugs; Autoimmune Disease, Cytokine release syndrome
- Recombinant protein of immune response regulators conjugated with CPP
- To down-regulate overly activated immune system